

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

Vancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - InMed Pharmaceuticals Inc. (**NASDAQ: INM**) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce Eric A. Adams, CEO of InMed, will be participating in the Water Tower Research Fireside Chat Series on May 23, 2023, at 1:00 pm ET.

This event is open access for all investors to participate. Topics will include:

- An overview of InMed's pharmaceutical development pipeline
- The BayMedica subsidiary and its importance to InMed's growth
- Upcoming catalysts for the Company

Interested parties can register for the event at the link below. Replays of the webcast will also be available after the event.

[PLEASE REGISTER HERE](#)

About InMed

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com.

About Water Tower Research

Water Tower Research is a shareholder communication and engagement platform powered by senior industry experts with significant Wall Street experience. We create, deliver, and maintain the information flow required to build and preserve relationships with every stakeholder and potential investor. Our foundation is built on Wall Street veterans using open digital distribution strategies that are accessible by everyone. "Research for the Other 99%™" opens the door to reach a much broader and diverse set of investors while helping to strengthen overall communications, transparency, and engagement. For more information, visit <https://www.watertowerresearch.com/home>.

Investor Contact:

Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: cclancy@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: the importance of the BayMedica subsidiary to the Company's growth; upcoming catalysts for the Company.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/166650>